Self-Guided Resilience-Building Energy Management to Enhance Well-being (RENEW) Intervention for People With Systemic Sclerosis (SSc)
Part of paid clinical trials in Ann Arbor, Michigan.
- Sponsor
- University of Michigan
- Study ID
- NCT07402863
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- RENEW — DEVICEThe RENEW program is 12-week program where participants are asked to access the app and set and track weekly healthy goals.
Study Details
The goal of this clinical trial is to gather information on the RENEW app used by people with scleroderma. Specifically, the researchers want to learn more about RENEW by collecting information about the rates of recruitment, retention of study participants information about study completion, and time spent accessing the app content.
Key Dates
- Start date
- Jan 28, 2025
- Status verified
- Apr 2026
- Primary completion
- Apr 28, 2025
- Completion
- Jul 28, 2025
Study Design
- Enrollment
- 43 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- OTHER
Arms
- Experimental: RENEWIndividuals with SSc who are interested and eligible will undergo an informed consent process and will be given access to the RENEW program via the app
Primary Outcome Measure
Feasibility based on study recruitment rate [ Time Frame: 12 weeks ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Michigan | Ann Arbor | Michigan | 48109 | - |
Find similar trials in Ann Arbor, MI
By research site
Related Studies
- A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)PHASE1 · Recruiting · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Aurora, Colorado
- RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic SclerosisPHASE1/PHASE2 · Recruiting · Cabaletta Bio · New Haven, Connecticut
- A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)PHASE1/PHASE2 · Recruiting · Nkarta, Inc. · Orange, California
- A Study of Nemolizumab for the Treatment of Adults With Systemic SclerosisPHASE2 · Recruiting · Galderma R&D · Ann Arbor, Michigan